To The Moon

Most new traders treat trading like a school exam—they think if they aren't right 80% or 90% of the time, they are failing. This belief causes beginners to hold losing trades forever just to avoid taking a loss and ruining their "win rate." Here is the secret: Win rate doesn't determine profitability—Risk-to-Reward Ratio (R:R) does. What Is Risk-to-Reward Ratio? Your Risk-to-Reward Ratio measures how much money you stand to lose versus how much money you stand to gain on a single trade. 1:1 R:R: You risk $10 to make $10. 1:2 R:R: You risk $10 to make $20. 1:3 R:R: You risk $10 to make $30. The 10-Trade Math Experiment Assume you take 10 trades risking $20 per trade with a 1:3 Risk-to-Reward Ratio. You have a terrible week and lose 6 out of 10 trades (a 40% win rate). Even though you were w

$Gold - main 2612(GCmain)$ doesn’t behave like a stock or a bond. There are no earnings to model, no dividends to discount, and no CEO to blame when the price drops. What gold reflects, more than anything else, is the collective confidence people have in the institutions managing money. When that confidence is high, gold is ignored. When it starts to crack, gold gets attention fast. $Silver - main 2609(SImain)$ follows the same logic but adds a wrinkle: it has a real industrial life. Solar panels, electronics, electric vehicles, medical equipment. That dual identity makes silver louder, more volatile, and more interesting to trade, but also harder to hold when the industrial cycle turns against it

These 4 stocks are down 40%-60% from its highs. But, EPS keeps going up every quarter for each of them too. Here's the 4 most undervalued stocks in $SPDR S&P 500 ETF Trust(SPY)$ : 1st stock is: $Fair Isaac(FICO)$ its down almost 40% right now. It has never printed a loss quarter and eps keeps accelerating. Honestly, it shouldn't even be down this year. It actually makes no sense to me. $FICO -Fiscal Q3 revenue $674M, up 26%. -GAAP EPS $10.45, up 41%. Non GAAP $12.18, up 42%. -$370M of free cash flow in a single quarter. -Platform ARR up 62% to $413M, now bigger than legacy for the first time. -Repurchased $1.96B of stock in the quarter. Yes, its very expensive this stock. So here's 3 more that are chea

$Moderna, Inc.(MRNA)$ just showed how explosive a successful cancer-vaccine catalyst can be. A $1,000 overnight options bet reportedly turned into more than $7.3M after Moderna announced a major Phase 3 win for its personalized cancer vaccine program. But here's the catch: This is an extremely high-risk game. Two cancer-vaccine Phase 3 programs have already failed in 2026, including $IOBT, which filed for Chapter 7 after missing its primary endpoint, and $IMMP, which discontinued its Phase 3 program for futility. So the next wave of catalysts could create massive winners — or wipe out years of work. Here are 5 biotech names with major clinical readouts ahead: 1. $CG Oncology Inc.(CGON)$ Oncolytic virus de

Only 12 of the 34 strongest movers with a market cap above $10B are still trading above all their major moving averages. That tells us something important: Headline strength is still concentrated. A handful of stocks continue to show strong relative strength since August 6, but the broader setup remains selective rather than broadly bullish. 🔥 The strongest RS names include: $SpaceX(SPCX)$ — Aerospace & Defense One of the strongest relative-strength names since Aug. 6. $TPG, Inc.(TPG)$ — Asset Management $Dell Technologies Inc.(DELL)$ — Computer Hardware $SUPER MICRO COMPUTER INC(SMCI)$ — Computer Hardware

Revenue growth is only the first step. The real compounding happens when a company can turn higher revenue into even faster FCF growth, and then turn that FCF growth into even faster FCF per share growth. 📈 That is where three powerful forces come together: Margin expansion + Buybacks + Multiple contraction A company doesn't necessarily need explosive revenue growth to generate strong long-term shareholder returns. If margins keep expanding, cash flow can grow faster than revenue. If management keeps buying back shares, FCF per share can grow even faster. And if the valuation multiple doesn't expand — or even contracts — the underlying business can still deliver strong returns. 🔥 The companies that stand out The following 24 companies show the characteristics of this kind of compounding mo